110 related articles for article (PubMed ID: 18393446)
1. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
VanScyoc WS; Holdgate GA; Sullivan JE; Ward WH
Biochemistry; 2008 Apr; 47(17):5017-27. PubMed ID: 18393446
[TBL] [Abstract][Full Text] [Related]
2. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
3. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
[TBL] [Abstract][Full Text] [Related]
4. An intrinsic ATPase activity of phospho-MEK-1 uncoupled from downstream ERK phosphorylation.
Rominger CM; Schaber MD; Yang J; Gontarek RR; Weaver KL; Broderick T; Carter L; Copeland RA; May EW
Arch Biochem Biophys; 2007 Aug; 464(1):130-7. PubMed ID: 17490600
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate dehydrogenase kinase isoform 2 activity limited and further inhibited by slowing down the rate of dissociation of ADP.
Bao H; Kasten SA; Yan X; Roche TE
Biochemistry; 2004 Oct; 43(42):13432-41. PubMed ID: 15491150
[TBL] [Abstract][Full Text] [Related]
6. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
[TBL] [Abstract][Full Text] [Related]
7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
9. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
[TBL] [Abstract][Full Text] [Related]
10. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
Fischmann TO; Smith CK; Mayhood TW; Myers JE; Reichert P; Mannarino A; Carr D; Zhu H; Wong J; Yang RS; Le HV; Madison VS
Biochemistry; 2009 Mar; 48(12):2661-74. PubMed ID: 19161339
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
13. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Ember B; Kamenecka T; LoGrasso P
Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
[TBL] [Abstract][Full Text] [Related]
14. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
[TBL] [Abstract][Full Text] [Related]
15. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
16. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia.
Morioka N; Tanabe H; Inoue A; Dohi T; Nakata Y
Neurochem Int; 2009 Sep; 55(4):226-34. PubMed ID: 19524113
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
19. Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.
Sheth PR; Liu Y; Hesson T; Zhao J; Vilenchik L; Liu YH; Mayhood TW; Le HV
Biochemistry; 2011 Sep; 50(37):7964-76. PubMed ID: 21793567
[TBL] [Abstract][Full Text] [Related]
20. Ascorbic acid 6-palmitate suppresses gap-junctional intercellular communication through phosphorylation of connexin 43 via activation of the MEK-ERK pathway.
Lee KM; Kwon JY; Lee KW; Lee HJ
Mutat Res; 2009 Jan; 660(1-2):51-6. PubMed ID: 19026667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]